Fed. Circ. Won't Review Invalidity Ruling Over Yaz Patent

Law360, New York (August 12, 2013, 3:13 PM EDT) -- The Federal Circuit on Monday refused to reconsider its ruling that claims in a patent related to Bayer AG's Yaz contraceptive were invalid, shooting down a bid for a rehearing in an infringement case the company brought against generic-drug makers.

A majority of Federal Circuit judges denied a combined petition lodged by Bayer Healthcare Pharmaceuticals Inc. and Bayer Schering Pharma AG, which sought an en banc rehearing of a decision handed down by the appeals court in April. In the contested decision, a three-judge panel found...
To view the full article, register now.